Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: GPCR modulators - Nxera Pharma

Next Previous
Drug Profile

Research programme: GPCR modulators - Nxera Pharma

Alternative Names: allosteric modulators of metabotropic glutamate receptor (5mGluR5) - Nxera Pharma; calcitonin gene-related peptide (CGRP) modulators - Nxera Pharma; CNS disorder therapeutics - Nxera Pharma; H4 receptor antagonist - Nxera Pharma; M1/M4 agonist - Nxera Pharma; mGlus NAM - Nxera Pharma; muscarinic M1 agonists - Nxera Pharma; Orexin OX1 receptor antagonist - Nxera Pharma; Orexin OX1/OX2 dual receptor agonists; Orexin OX2 agonists - Nxera Pharma; OX-1 antagonist - Nxera Pharma

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heptares Therapeutics
  • Developer AbbVie; Medical Research Council; Nxera Pharma; Shire; Takeda; Tempero Bio
  • Class Antimigraines; Anxiolytics; Drug withdrawal therapies; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2A receptor antagonists; Calcitonin gene-related peptide antagonists; G protein-coupled receptor modulators; Histamine H4 receptor antagonists; Metabotropic glutamate receptor 5 antagonists; Metabotropic glutamate receptor 5 modulators; Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anxiety disorders; Atopic dermatitis; Autistic disorder; CNS disorders; Cocaine-related disorders; Cognition disorders; Depressive disorders; Migraine; Obsessive-compulsive disorders; Parkinson's disease; Psychotic disorders; Sleep disorders; Substance-related disorders; Unspecified

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for preclinical development in CNS-disorders in United Kingdom
  • 28 Dec 2024 No recent reports of development identified for research development in Anxiety-disorders in Unknown (PO)
  • 28 Dec 2024 No recent reports of development identified for research development in Substance-related disorders in Unknown (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top